EMS SA:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】EMS SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3304)・商品コード:DATA904C3304
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:55
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥55,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥82,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
EMS SA (EMS) is a pharmaceutical company, which is focused in the development of products for improvement of health and well-being of the population. It operates in prescription segments generics, branded pharmaceuticals, OTC and hospital. It has presence in the US market through Brace Pharma, a company focused on radical innovation. The company has production units in Sao Bernardo do Campo, in Jaguariuna and Hortolandia (SP), Novamed, located in Manaus (AM); and in Brasilia (DF). It exports to over 40 countries globally. EMS is headquartered in Hortolandia, Brazil.

EMS SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
EMS SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
EMS SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
EMS SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
EMS SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
EMS SA, Medical Devices Deals, 2012 to YTD 2018 10
EMS SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
EMS SA, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
ReViral Raises USD55 Million in Series B Financing 15
Antiva Biosciences Raises USD15 Million in Series C-1 Financing 17
Precision BioSciences Raises USD110 Million in Venture Financing 19
Avrobio Raises USD60 Million in Series B Venture Financing 22
Antiva Biosciences Raises USD22 Million in Series C Financing 24
Avidity Biosciences Raises USD10 Million in Series B Venture Financing 25
F2G Raises USD60 Million in Venture Financing 27
Zymeworks Raises USD61.5 Million in Series A Financing 29
Navitor Pharma Raises USD33 Million in Series B Financing 31
miRagen Therapeutics Raises USD41 Million in Series C Financing 33
Therabron Therapeutics Raises USD6.75 Million in Second Tranche of Series B Financing Round 35
ReViral Raises USD21 Million in Series A Financing Round 36
Unum Therapeutics Raises USD65 Million in Series B Financing 37
Therabron Therapeutics Raises USD11 Million in Series B Venture Financing 39
Avidity NanoMedicines Raises USD6 Million in Series B Venture Financing 40
Tyrogenex Raises USD15 Million in Series D Venture Financing 41
Gliknik Raises Funds through Venture Financing 42
Licensing Agreements 43
Iroko Pharma Enters into Licensing Agreement with EMS for Zorvolex 43
BioAlliance Pharma Enters into Licensing Agreement with EMS for Sitavig 44
Equity Offering 45
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 45
Acquisition 47
EMS to Acquire 93.7% Stake in Galenika for USD19 Million in Tender Offer 47
Government of Serbia to Sell Majority Stake in Galenika 48
Dermapharm Rumored To Acquire Galenika 49
Government of Serbia Plans To Sell 20% Stake In Galenika, Prescription Drug Manufacturer 50
EMS SA – Key Competitors 51
EMS SA – Key Employees 52
EMS SA – Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Joint Venture 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
EMS SA, Pharmaceuticals & Healthcare, Key Facts 2
EMS SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
EMS SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
EMS SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
EMS SA, Deals By Therapy Area, 2012 to YTD 2018 8
EMS SA, Medical Devices Deals, 2012 to YTD 2018 10
EMS SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReViral Raises USD55 Million in Series B Financing 15
Antiva Biosciences Raises USD15 Million in Series C-1 Financing 17
Precision BioSciences Raises USD110 Million in Venture Financing 19
Avrobio Raises USD60 Million in Series B Venture Financing 22
Antiva Biosciences Raises USD22 Million in Series C Financing 24
Avidity Biosciences Raises USD10 Million in Series B Venture Financing 25
F2G Raises USD60 Million in Venture Financing 27
Zymeworks Raises USD61.5 Million in Series A Financing 29
Navitor Pharma Raises USD33 Million in Series B Financing 31
miRagen Therapeutics Raises USD41 Million in Series C Financing 33
Therabron Therapeutics Raises USD6.75 Million in Second Tranche of Series B Financing Round 35
ReViral Raises USD21 Million in Series A Financing Round 36
Unum Therapeutics Raises USD65 Million in Series B Financing 37
Therabron Therapeutics Raises USD11 Million in Series B Venture Financing 39
Avidity NanoMedicines Raises USD6 Million in Series B Venture Financing 40
Tyrogenex Raises USD15 Million in Series D Venture Financing 41
Gliknik Raises Funds through Venture Financing 42
Iroko Pharma Enters into Licensing Agreement with EMS for Zorvolex 43
BioAlliance Pharma Enters into Licensing Agreement with EMS for Sitavig 44
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 45
EMS to Acquire 93.7% Stake in Galenika for USD19 Million in Tender Offer 47
Government of Serbia to Sell Majority Stake in Galenika 48
Dermapharm Rumored To Acquire Galenika 49
Government of Serbia Plans To Sell 20% Stake In Galenika, Prescription Drug Manufacturer 50
EMS SA, Key Competitors 51
EMS SA, Key Employees 52
EMS SA, Other Locations 53
EMS SA, Subsidiaries 53
EMS SA, Joint Venture 54

List of Figures
EMS SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
EMS SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
EMS SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
EMS SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
EMS SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
EMS SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
EMS SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
EMS SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
EMS SA, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[EMS SA:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3304)販売に関する免責事項を必ずご確認ください。
★調査レポート[EMS SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆